Related Experiment Video
Updated: Sep 29, 2025

Constructing Thioether/Vinyl Sulfide-tethered Helical Peptides Via Photo-induced Thiol-ene/yne Hydrothiolation
Published on: August 1, 2018
Structural Modifications on Chalcone Framework for Developing New Class of Cholinesterase Inhibitors
Ginson George1, Vishal Payyalot Koyiparambath1, Sunitha Sukumaran1
1Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, AIMS Health Sciences Campus, Amrita Vishwa Vidyapeetham, Kochi 682 041, India.
Chalcones, versatile compounds with drug-like properties, show promise for Alzheimer's disease (AD) treatment. This review highlights their potential as privileged structures for developing new AD therapies, focusing on cholinesterase inhibition.
Area of Science:
- Medicinal Chemistry
- Neuroscience
- Pharmacology
Background:
- Chalcones are privileged scaffolds in drug discovery due to their diverse pharmacological activities.
- Alzheimer's disease (AD) drug development is a significant research area for chalcone derivatives.
- Chalcones offer advantages like small molecular size, synthetic accessibility, and modifiability.
Purpose of the Study:
- To review recent evidence supporting chalcones as privileged structures in Alzheimer's disease (AD) drug development.
- To summarize various chalcone-derived analogs and their structure-activity relationships.
- To emphasize the importance of specific functionalities in cholinesterase inhibition for AD treatment.
Main Methods:
- Literature review of chalcone derivatives and their pharmacological activities.
- Analysis of structure-activity relationships for cholinesterase inhibition.
- Categorization of different chalcone analog classes.
Main Results:
- Chalcones exhibit significant potential for Alzheimer's disease (AD) therapy.
- Specific structural features of chalcones are crucial for cholinesterase inhibition.
- Numerous chalcone analogs have been synthesized and evaluated for AD treatment.
Conclusions:
- Chalcones represent a promising class of compounds for the development of novel Alzheimer's disease (AD) therapeutics.
- Medicinal chemists can leverage this review to design and synthesize new chalcone candidates.
- Further research into chalcone derivatives could lead to effective treatments for AD.
More Related Videos
06:31Highly Stereoselective Synthesis of 1,6-Ketoesters Mediated by Ionic Liquids: A Three-component Reaction Enabling Rapid Access to a New Class of Low Molecular Weight Gelators
Published on: November 27, 2015
11:44Synthesis and Structure Determination of µ-Conotoxin PIIIA Isomers with Different Disulfide Connectivities
Published on: October 2, 2018
Related Concept Videos
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Indirect-Acting Cholinergic Agonists: Mechanism of Action
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinesterases: Distribution and Function
Prochirality